To evaluate the role of CD8+ T-cells in CTSS-mediated tumor immunity, we administered anti-CD8 antibodies (Anti-mCD8-mIgG2a InvivoFit) in an orthotopic CRC mouse model. Here, CD8A is linked to neoplasm.